Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 39.5% - Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) was up 39.5% during trading on Monday . The company traded as high as $37.83 and last traded at $32.12. Approximately 4,420,354 shares changed hands during mid-day trading, an increase of 556% from the average daily volume of 674,270 shares. The stock had previously closed at $23.03.

Analyst Ratings Changes

A number of research firms have recently weighed in on TNXP. Noble Financial reaffirmed an "outperform" rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a research note on Thursday. StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a "sell" rating on the stock.

Tonix Pharmaceuticals Stock Performance

The firm has a 50 day moving average price of $18.44 and a 200-day moving average price of $19.79. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market cap of $56.84 million, a P/E ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The company had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.20 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in TNXP. PFG Investments LLC bought a new position in Tonix Pharmaceuticals in the 4th quarter worth approximately $72,000. Commonwealth Equity Services LLC bought a new stake in Tonix Pharmaceuticals in the 4th quarter valued at $40,000. Geode Capital Management LLC grew its position in Tonix Pharmaceuticals by 1,600.1% in the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock worth $650,000 after purchasing an additional 1,855,907 shares during the last quarter. Northern Trust Corp acquired a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at about $162,000. Finally, Jane Street Group LLC lifted its stake in shares of Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock valued at $548,000 after buying an additional 1,635,119 shares during the period. 82.26% of the stock is owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads